<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02462863</url>
  </required_header>
  <id_info>
    <org_study_id>2014-6677</org_study_id>
    <nct_id>NCT02462863</nct_id>
  </id_info>
  <brief_title>Treatment of Type 2 Diabetes With Immunonutrients</brief_title>
  <official_title>Treatment of Type 2 Diabetes With Immunonutrients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christ Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christ Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if the nutrients arginine and fish oil&#xD;
      will reverse or improve diabetes and to find out what additional good or bad effects a&#xD;
      combination of arginine and fish oil may have. Both arginine and fish oil are common&#xD;
      nutrients taken by normal people on a frequent basis. However, they have not been used in&#xD;
      combination in the proposed doses to reverse diabetes once it is established. This study has&#xD;
      been approved by the Food and Drug Administration (FDA investigational new drug [IND] 12191).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis for the proposed studies is that selected immunonutrients will reduce glucose&#xD;
      levels in type 2 diabetes and provide the basis for safe and effective treatment. This should&#xD;
      result in an increased resistance to infection, decrease in cardiovascular disease and&#xD;
      improve mortality as will be shown in subsequent studies.&#xD;
&#xD;
      Specific Aim 1: To demonstrate proof of concept that supplementation of a normal (diabetic)&#xD;
      diet with oral arginine and fish oil will reverse or at least improve glucose control, and&#xD;
      improve hemoglobin A1c (HgA1c) in patients with type 2 diabetes.&#xD;
&#xD;
      Specific Aim 2: To determine the relationship of plasma amino acid profiles and concentration&#xD;
      of selected fatty acids in cellular (RBC) membranes to the resolution of type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2016</start_date>
  <completion_date type="Actual">June 7, 2017</completion_date>
  <primary_completion_date type="Actual">May 4, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>subjects will take arginine 4.5 grams BID plus Fish Oil 7 grams daily</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of type 2 diabetes</measure>
    <time_frame>6 months</time_frame>
    <description>Decrease in hemoglobin A1c and glucose.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Immunonutrient treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of arginine and fish oil.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Arginine and fish oil</intervention_name>
    <description>Dietary supplements</description>
    <arm_group_label>Immunonutrient treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult onset diabetics, BMI under 35 with stable glycemic and hypertensive control.&#xD;
             Must be receiving medication for diabetes, be free of cardiac problems such as&#xD;
             myocardial infarction, atrial fibrillation or flutter, severe hepatic or&#xD;
             gastrointestinal disease, and have a glomerular filtration rate (GFR) of greater than&#xD;
             50 ml/minute. Must have an LDL-C of less than 120 mg/ml with or without treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic infection, past history of cancer except cured skin cancer. Active&#xD;
             inflammation processes will also be excluded. Pregnant or nursing women will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Wesley Alexander, M.D., Sc.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Meenakshi Iyer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Christ Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>J. Wesley Alexander, M.D., Sc.D.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Christ Hospital</investigator_affiliation>
    <investigator_full_name>Linda H. Martin, RN, BSN, MBA,</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>fish oil</keyword>
  <keyword>arginine</keyword>
  <keyword>hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

